BRPI0409501A - compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças - Google Patents

compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças

Info

Publication number
BRPI0409501A
BRPI0409501A BRPI0409501-4A BRPI0409501A BRPI0409501A BR PI0409501 A BRPI0409501 A BR PI0409501A BR PI0409501 A BRPI0409501 A BR PI0409501A BR PI0409501 A BRPI0409501 A BR PI0409501A
Authority
BR
Brazil
Prior art keywords
compounds
treatment
radicals
cancer
diseases
Prior art date
Application number
BRPI0409501-4A
Other languages
English (en)
Inventor
Catherine Tachdjian
Jianhua Guo
Mohamed Jelal
Hussien A Al-Shamma
Andrea Fanjul Giachino
Karine Jakubowicz-Jaillardon
Quig Chen
James W Zapf
Magnus Pfahl
Original Assignee
Incyte San Diego Inc
Ortho Micneil Pharmaceutical I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc, Ortho Micneil Pharmaceutical I filed Critical Incyte San Diego Inc
Publication of BRPI0409501A publication Critical patent/BRPI0409501A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS ISOCROMANOS SUBSTITUìDOS PARA O TRATAMENTO DE DESORDENS METABóLICAS, DE CáNCER E DE OUTRAS DOENçAS". A presente invenção se refere aos novos compostos heterocíclicos cuja estrutura corresponde à fórmula (I), no qual os radicais Ar~ 1~, são os radicais isocromanos substituídos, os radicais Ar~ 2~, são os radicais arila ou heteroarila, e o HAr é um radical 2,4-tiazolidinadiona ou 2-tioxo-imidazolidin-4-ona, 2,4imidazolidinadiona ou 2-tioxo-imidazolidina-4-ona. Os compostos correspondentes à fórmula (I) podem apresentar uma atividade biológica que controla, de forma vantajosa, o metabolismo dos carboidratos, incluindo os níveis de glicose sérica, e o metabolismo dos lipídios, e podem ser utilizados para o tratamento da hiperlipidemia e/ou hipercolesterolemia, e da diabete Tipo 11. Os compostos correspondentes à fórmula (I) podem igualmente ser utilizados no tratamento de doenças de proliferação descontrolada, incluindo o câncer.
BRPI0409501-4A 2003-04-18 2004-04-19 compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças BRPI0409501A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46438803P 2003-04-18 2003-04-18
PCT/US2004/012284 WO2004093809A2 (en) 2003-04-18 2004-04-19 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Publications (1)

Publication Number Publication Date
BRPI0409501A true BRPI0409501A (pt) 2006-04-18

Family

ID=33310879

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409501-4A BRPI0409501A (pt) 2003-04-18 2004-04-19 compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças

Country Status (13)

Country Link
US (1) US20050038098A1 (pt)
EP (1) EP1643993A2 (pt)
JP (1) JP2006523724A (pt)
KR (1) KR20060036896A (pt)
CN (1) CN1774246A (pt)
AU (1) AU2004232326A1 (pt)
BR (1) BRPI0409501A (pt)
CA (1) CA2522759A1 (pt)
MX (1) MXPA05011242A (pt)
NO (1) NO20055307L (pt)
RU (1) RU2005135850A (pt)
WO (1) WO2004093809A2 (pt)
ZA (1) ZA200509355B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384825A (zh) 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基－噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
JP2004523571A (ja) * 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
CN102329192A (zh) * 2011-09-30 2012-01-25 山东天一化学股份有限公司 溴化苄的合成方法
EP2854526B1 (en) * 2012-03-22 2018-04-25 vTv Therapeutics LLC Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
CN105315223B (zh) * 2015-11-06 2017-08-25 河南大学 一种高立体和高对映选择性噻唑烷二酮类化合物、其制备方法及应用
US10231947B2 (en) * 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) * 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) * 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CN116693520B (zh) * 2023-05-10 2026-07-14 五邑大学 一种色酮噻唑二酮类化合物及其制备方法、药物组合物和应用
CN116693521B (zh) * 2023-05-10 2026-07-14 五邑大学 一种含色酮结构的噻唑烷二酮乙酯类化合物及其制备方法、药物组合物和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
DE3874257T2 (de) * 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
EP0595868B1 (en) * 1991-07-22 1998-11-25 Pfizer Inc. Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
ES2130597T3 (es) * 1994-02-17 1999-07-01 American Home Prod Derivados de bifenilo sustituido como inhibidores de la fosfodiesterasa.
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
US6127415A (en) * 1996-07-08 2000-10-03 Galderma Research & Development, S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
CN1384825A (zh) * 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基－噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
JP2004523571A (ja) * 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases

Also Published As

Publication number Publication date
NO20055307L (no) 2005-12-21
RU2005135850A (ru) 2006-06-10
ZA200509355B (en) 2007-03-28
EP1643993A2 (en) 2006-04-12
WO2004093809A2 (en) 2004-11-04
MXPA05011242A (es) 2006-07-06
CN1774246A (zh) 2006-05-17
JP2006523724A (ja) 2006-10-19
WO2004093809A3 (en) 2005-04-21
NO20055307D0 (no) 2005-11-10
KR20060036896A (ko) 2006-05-02
US20050038098A1 (en) 2005-02-17
CA2522759A1 (en) 2004-11-04
AU2004232326A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
Eckel Myokines in metabolic homeostasis and diabetes
Majumder et al. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury
BRPI0513836A (pt) composto, métodos de tratar, controlar ou prevenir cáncer, uma doença associada com angiogênese indesejada, e uma doença ou distúrbio mediado por pde 4, e de reduzir ou inibir o nìvel ou a atividade de pde 4 em um paciente, e, composição farmacêutica
Lirdprapamongkol et al. A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells
BR0308974A (pt) Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
MA27707A1 (fr) Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
BRPI0412689A (pt) derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele
CA2633440C (en) 1,3-dioxane carboxylic acids
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
BR0014843A (pt) Composto, composição farmacêutica, métodos para tratar ou prevenir o câncer em um mamìfero, uma doença em que a angiogênese está implicada, a vascularização retinal, a retinipatia diabética, a degeneração macular relacionada com a idade, doença inflamatória, uma doença ou condição dependente de tirosina quinase e, patologias relacionadas com o osso, processo para fabricar uma composição farmacêutica, e, método para reduzir ou impedir o dano de tecido que segue um evento isquêmico
BR0009433A (pt) Inibidores de sorbitol desidrogenase
BRPI0416361A (pt) métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente
BRPI0511757A (pt) derivados de arila e heteroarila substituìdos como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a este
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
BR112021016782A2 (pt) Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica
DE60325740D1 (de) Verwendung von protein-kinase-n-beta
JP2005513026A5 (pt)
Zhao et al. Hydroxysafflor yellow A attenuates high glucose-induced pancreatic β-cells oxidative damage via inhibiting JNK/c-jun signaling pathway
CY1111576T1 (el) Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps)
BRPI0519769A2 (pt) compostos orgÂnicos
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
Kirkpatrick et al. Inhibition of the histone demethylase KDM4B leads to activation of KDM1A, attenuates bacterial-induced pro-inflammatory cytokine release, and reduces osteoclastogenesis
BR112012028445A2 (pt) compostos de heteroarila bicíclica como moduladores de gpr119
WO2004093809A3 (en) Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]